Scientific Reports (Jul 2022)

Assessment of diagnostic utility of serum hemeoxygenase-1 measurement for acute exacerbation of interstitial pneumonias

  • Yuki Kata,
  • Yu Hara,
  • Yoichi Tagami,
  • Aya Yabe,
  • Kota Murohashi,
  • Ryo Nagasawa,
  • Kentaro Nakashima,
  • Hiroaki Fujii,
  • Yusuke Saigusa,
  • Masafumi Shiida,
  • Keisuke Watanabe,
  • Nobuyuki Horita,
  • Nobuaki Kobayashi,
  • Takeshi Kaneko

DOI
https://doi.org/10.1038/s41598-022-17290-0
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 7

Abstract

Read online

Abstract The present study aimed to evaluate whether serum heme oxygenase (HO)-1 could be a reliable blood biomarker for diagnosing acute exacerbations (AEs) of both idiopathic interstitial pneumonia (IIP) and secondary interstitial pneumonia (SIP). Serum HO-1 levels of newly diagnosed patients with IP were measured, and the relationships between serum HO-1 and other serum biomarkers and high-resolution CT scores, were evaluated. Blood samples were collected from 90 patients with IIP, including 32 having an AE, and 32 with SIP, including 9 having an AE. The patients having an AE had significantly higher HO-1 levels than those not having an AE (35.2 ng/mL vs. 16.4 ng/mL; p < 0.001). On receiver operating characteristics (ROC) curve analysis for serum HO-1 ability to detect an AE, the area under the ROC curve (AUC) was 0.87 in patients with IIPs and 0.86 in those with SIPs. Also, in patients with both IIPs and SIPs, the combination of the serum HO-1 level and the GGO score showed favorable AUCs (IIPs: 0.92, SIPs: 0.83), though HO-1-not-including model (combination of LDH and GGO) also showed acceptable AUCs. Serum HO-1 could be a clinically useful biomarker for the accurate diagnosis of patients with AEs.